Table 3.
Response by RECIST criteria and median progression-free and overall survival results
| Response by RECIST | |||||||
|---|---|---|---|---|---|---|---|
|
| |||||||
| N | Partial Response | Stable Disease | Progressive Disease | ||||
|
|
|||||||
| N | No. | % | No. | % | No. | % | |
| Liposarcoma | 17 | 0 | 0 | 14 | 82 | 3 | 18 |
| Leiomyosarcoma | 13 | 1 | 8 | 12 | 92 | 0 | 0 |
| MFH | 13 | 0 | 0 | 7 | 54 | 6 | 46 |
| Total | 43 | 1 | 2 | 33 | 77 | 9 | 21 |
| Progression-Free and Overall Survival | |||||
|---|---|---|---|---|---|
|
| |||||
| N | Progression-Free Survival, months | Overall Survival, months | |||
|
|
|||||
| N | Exponential, Median (95% CI) |
Kaplan-Meier, Median (95% CI) |
Exponential, Median (95% CI) |
Kaplan-Meier, Median (95% CI) |
|
| Liposarcoma | 18 | 3.4 (2.2-5.8) | 3.9 (2.8-4.4) | 16.9 (10.1-33.8) | 18.6 (5.2-27.7) |
| Leiomyosarcoma | 15 | 3.7 (2.4-6.7) | 4.2 (2.0-8.3) | 9.2 (5.7-17.3) | 10.1 (4.1-11.9) |
| MFH | 14 | 4.6 (2.8-8.6) | 2.5 (1.4-5.5) | 15.3 (9.0-31.9) | 13.6 (3.1-……) |
For RECIST results, 1 liposarcoma, 2 leiomyosarcoma, and 1 MFH patient were not assessable for response. In addition, 1 enrolled patient with fibrosarcoma was not included. For survival results, 1 enrolled patient with fibrosarcoma was not included.